Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Cancer cells gain a growth advantage through the so-called Warburg effect by shifting glucose metabolism from oxidative phosphorylation to aerobic glycolysis. Hypoxia-inducible factor 1 (HIF-1) has been suggested to function in metabolic reprogramming; however, the underlying mechanism has not been fully elucidated. We found that the aberrant expression of wild-type isocitrate dehydrogenase 3α (IDH3α), a subunit of the IDH3 heterotetramer, decreased α-ketoglutarate levels and increased the stability and transactivation activity of HIF-1α in cancer cells. The silencing of IDH3α significantly delayed tumor growth by suppressing the HIF-1-mediated Warburg effect and angiogenesis. IDH3α expression was associated with the poor postoperative overall survival of lung and breast cancer patients. These results justify the exploitation of IDH3 as a novel target for the diagnosis and treatment of cancers.

Original publication

DOI

10.1038/onc.2014.411

Type

Journal article

Journal

Oncogene

Publication Date

03/09/2015

Volume

34

Pages

4758 - 4766

Keywords

Animals, Breast Neoplasms, Cell Line, Tumor, Cell Proliferation, Female, Gene Expression Regulation, Neoplastic, Glucose, Glycolysis, Humans, Hypoxia-Inducible Factor 1, alpha Subunit, Isocitrate Dehydrogenase, Lung Neoplasms, Mice, Neovascularization, Pathologic, Oxidative Phosphorylation